About Us Services Careers FAQ Contact Us 0
Home Pharmaceuticals High Potency Active Pharmaceutical Ingredients Market to Expand at USD 48.53 billion by 20
High Potency Active Pharmaceutical Ingredients Market

High Potency Active Pharmaceutical Ingredients Market Size, Share & Trends Analysis Report By Product (Synthetic, Biological), By Manufacturer Type (In-house, Outsourced), By Drug Type (Innovative, Generic), By Therapeutic Applications (Oncology, Hormonal, Glaucoma, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRPH54803DR
Last Updated : August 10, 2023
Author : Straits Research
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global High Potency Active Pharmaceutical Ingredients Market Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Synthetic
        1. By Value
      3. Biological
        1. By Value
    3. By Manufacturer Type
      1. Introduction
        1. Manufacturer Type By Value
      2. In-house
        1. By Value
      3. Outsourced
        1. By Value
    4. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Innovative
        1. By Value
      3. Generic
        1. By Value
    5. By Therapeutic Applications
      1. Introduction
        1. Therapeutic Applications By Value
      2. Oncology
        1. By Value
      3. Hormonal
        1. By Value
      4. Glaucoma
        1. By Value
      5. Others
        1. By Value
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Synthetic
        1. By Value
      3. Biological
        1. By Value
    3. By Manufacturer Type
      1. Introduction
        1. Manufacturer Type By Value
      2. In-house
        1. By Value
      3. Outsourced
        1. By Value
    4. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Innovative
        1. By Value
      3. Generic
        1. By Value
    5. By Therapeutic Applications
      1. Introduction
        1. Therapeutic Applications By Value
      2. Oncology
        1. By Value
      3. Hormonal
        1. By Value
      4. Glaucoma
        1. By Value
      5. Others
        1. By Value
    6. U.S.
      1. By Product
        1. Introduction
          1. Product By Value
        2. Synthetic
          1. By Value
        3. Biological
          1. By Value
      2. By Manufacturer Type
        1. Introduction
          1. Manufacturer Type By Value
        2. In-house
          1. By Value
        3. Outsourced
          1. By Value
      3. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Innovative
          1. By Value
        3. Generic
          1. By Value
      4. By Therapeutic Applications
        1. Introduction
          1. Therapeutic Applications By Value
        2. Oncology
          1. By Value
        3. Hormonal
          1. By Value
        4. Glaucoma
          1. By Value
        5. Others
          1. By Value
    7. Canada
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Synthetic
        1. By Value
      3. Biological
        1. By Value
    3. By Manufacturer Type
      1. Introduction
        1. Manufacturer Type By Value
      2. In-house
        1. By Value
      3. Outsourced
        1. By Value
    4. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Innovative
        1. By Value
      3. Generic
        1. By Value
    5. By Therapeutic Applications
      1. Introduction
        1. Therapeutic Applications By Value
      2. Oncology
        1. By Value
      3. Hormonal
        1. By Value
      4. Glaucoma
        1. By Value
      5. Others
        1. By Value
    6. U.K.
      1. By Product
        1. Introduction
          1. Product By Value
        2. Synthetic
          1. By Value
        3. Biological
          1. By Value
      2. By Manufacturer Type
        1. Introduction
          1. Manufacturer Type By Value
        2. In-house
          1. By Value
        3. Outsourced
          1. By Value
      3. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Innovative
          1. By Value
        3. Generic
          1. By Value
      4. By Therapeutic Applications
        1. Introduction
          1. Therapeutic Applications By Value
        2. Oncology
          1. By Value
        3. Hormonal
          1. By Value
        4. Glaucoma
          1. By Value
        5. Others
          1. By Value
    7. Germany
    8. France
    9. Spain
    10. Italy
    11. Russia
    12. Nordic
    13. Benelux
    14. Rest of Europe
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Synthetic
        1. By Value
      3. Biological
        1. By Value
    3. By Manufacturer Type
      1. Introduction
        1. Manufacturer Type By Value
      2. In-house
        1. By Value
      3. Outsourced
        1. By Value
    4. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Innovative
        1. By Value
      3. Generic
        1. By Value
    5. By Therapeutic Applications
      1. Introduction
        1. Therapeutic Applications By Value
      2. Oncology
        1. By Value
      3. Hormonal
        1. By Value
      4. Glaucoma
        1. By Value
      5. Others
        1. By Value
    6. China
      1. By Product
        1. Introduction
          1. Product By Value
        2. Synthetic
          1. By Value
        3. Biological
          1. By Value
      2. By Manufacturer Type
        1. Introduction
          1. Manufacturer Type By Value
        2. In-house
          1. By Value
        3. Outsourced
          1. By Value
      3. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Innovative
          1. By Value
        3. Generic
          1. By Value
      4. By Therapeutic Applications
        1. Introduction
          1. Therapeutic Applications By Value
        2. Oncology
          1. By Value
        3. Hormonal
          1. By Value
        4. Glaucoma
          1. By Value
        5. Others
          1. By Value
    7. Korea
    8. Japan
    9. India
    10. Australia
    11. Taiwan
    12. South East Asia
    13. Rest of Asia-Pacific
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Synthetic
        1. By Value
      3. Biological
        1. By Value
    3. By Manufacturer Type
      1. Introduction
        1. Manufacturer Type By Value
      2. In-house
        1. By Value
      3. Outsourced
        1. By Value
    4. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Innovative
        1. By Value
      3. Generic
        1. By Value
    5. By Therapeutic Applications
      1. Introduction
        1. Therapeutic Applications By Value
      2. Oncology
        1. By Value
      3. Hormonal
        1. By Value
      4. Glaucoma
        1. By Value
      5. Others
        1. By Value
    6. UAE
      1. By Product
        1. Introduction
          1. Product By Value
        2. Synthetic
          1. By Value
        3. Biological
          1. By Value
      2. By Manufacturer Type
        1. Introduction
          1. Manufacturer Type By Value
        2. In-house
          1. By Value
        3. Outsourced
          1. By Value
      3. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Innovative
          1. By Value
        3. Generic
          1. By Value
      4. By Therapeutic Applications
        1. Introduction
          1. Therapeutic Applications By Value
        2. Oncology
          1. By Value
        3. Hormonal
          1. By Value
        4. Glaucoma
          1. By Value
        5. Others
          1. By Value
    7. Turkey
    8. Saudi Arabia
    9. South Africa
    10. Egypt
    11. Nigeria
    12. Rest of MEA
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Synthetic
        1. By Value
      3. Biological
        1. By Value
    3. By Manufacturer Type
      1. Introduction
        1. Manufacturer Type By Value
      2. In-house
        1. By Value
      3. Outsourced
        1. By Value
    4. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Innovative
        1. By Value
      3. Generic
        1. By Value
    5. By Therapeutic Applications
      1. Introduction
        1. Therapeutic Applications By Value
      2. Oncology
        1. By Value
      3. Hormonal
        1. By Value
      4. Glaucoma
        1. By Value
      5. Others
        1. By Value
    6. Brazil
      1. By Product
        1. Introduction
          1. Product By Value
        2. Synthetic
          1. By Value
        3. Biological
          1. By Value
      2. By Manufacturer Type
        1. Introduction
          1. Manufacturer Type By Value
        2. In-house
          1. By Value
        3. Outsourced
          1. By Value
      3. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Innovative
          1. By Value
        3. Generic
          1. By Value
      4. By Therapeutic Applications
        1. Introduction
          1. Therapeutic Applications By Value
        2. Oncology
          1. By Value
        3. Hormonal
          1. By Value
        4. Glaucoma
          1. By Value
        5. Others
          1. By Value
    7. Mexico
    8. Argentina
    9. Chile
    10. Colombia
    11. Rest of LATAM
    1. High Potency Active Pharmaceutical Ingredients Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. BASF SE
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. CordenPharma International
    3. CARBOGEN AMCIS AG
    4. Pfizer, Inc.
    5. Teva Pharmaceutical Industries Ltd.
    6. Albany Molecular Research, Inc.
    7. Sun Pharmaceutical Industries, Ltd.
    8. Sanofi
    9. Merck & Co., Inc.
    10. F. Hoffmann-La Roche Ltd.
    11. Novartis AG
    12. Bristol-Myers Squibb Company
    13. Lonza
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
The global active pharmaceutical ingredients (API) market size was valued at USD 209.19 million in 2022. It is expected to reach USD 487.01 million by 2031, growing at a CAGR of 6.05% during the forecast period (2023–2031). Any substance or co
Buy Now
Global Report
The global active pharmaceutical ingredients CDMO market size was valued at USD 93.42 billion in 2022. It is estimated to reach USD 164.65 billion by 2031, growing at a CAGR of 6.5% during the forecast period (2023–2031). According to the FDA,
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.